(2,4-Dimethoxypyrimidin-5-yl)boronic acid → HCID 86703222, compound
Reaction equation
Br[C:2]1[N:6]([CH:7]([CH3:9])[CH3:8])[C:5]2[CH:10]([C:23]3[CH:30]=[CH:29][C:26]([C:27]#[N:28])=[C:25]([F:31])[CH:24]=3)[N:11]([C:14]3[C:15](=[O:22])[N:16]([CH3:21])[CH:17]=[C:18]([Cl:20])[CH:19]=3)[C:12](=[O:13])[C:4]=2[CH:3]=1.[CH3:32][O:33][C:34]1[N:39]=[C:38]([O:40][CH3:41])[C:37](B(O)O)=[CH:36][N:35]=1.BrC1N(C(C)C)C2C(C3C=CC(Cl)=CC=3)N(C3C=C(Cl)C=CC=3C)C(=O)C=2C=1.COC1C(B2OC(C)(C)C(C)(C)O2)=CN=C(N)N=1>>[Cl:20][C:18]1[CH:19]=[C:14]([N:11]2[C:12](=[O:13])[C:4]3[CH:3]=[C:2]([C:37]4[C:38]([O:40][CH3:41])=[N:39][C:34]([O:33][CH3:32])=[N:35][CH:36]=4)[N:6]([CH:7]([CH3:9])[CH3:8])[C:5]=3[CH:10]2[C:23]2[CH:30]=[CH:29][C:26]([C:27]#[N:28])=[C:25]([F:31])[CH:24]=2)[C:15](=[O:22])[N:16]([CH3:21])[CH:17]=1Participants
5
Reactant 4
Product 1
Procedure
The title compound was prepared in analogy to the procedure described for Example 25 but 4-[2-bromo-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-1-isopropyl-4-oxo-1,4,5,6-tetrahydro-pyrrolo[3,4-b]pyrrol-6-yl]-2-fluoro-benzonitrile (Intermediate BD) and 2,4-dimethoxypyrimidine-5-boronic acid were used instead of 2-bromo-5-(5-chloro-2-methyl-phenyl)-6-(4-chloro-phenyl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-b]pyrrol-4-one and 4-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrimidin-2-ylamine respectively to afford the title compound as a white solid. tR: 1.04 min (HPLC 3); ESI-MS: tR=1.01 min, [M+H]+ 563/565 (LC-MS 1); TLC: Rf=0.27 (EtOAc).
Workup
- customThe title compound was prepared in analogy to the procedure
Sources & evidence
- ORD record
- ord-a0b281a580c94d72b22a85fe3aac0713
- Source dataset
- uspto-grants-2016_06
- Patent number
- US09365576B2
Reaction notes
Loading…